MiNK Therapeutics Third Quarter 2026 Financial Results - MINK THERAPEUTICS INC

Financial Performance:

• Reported first pre-commercial product revenue from Agent 797 via the Named Patient Program, with demand expected to fluctuate based on physician requests and regulatory approvals.
• Net loss for Q3 2026 was $2.6 million ($0.50/share), a reduction from $2.9 million ($0.65/share) in the prior year period.
• Cash and cash equivalents stood at $7.5 million as of quarter-end, down from $8.8 million in Q2 2026.
• Cash used in operations was $1.3 million, a significant decrease from $2.1 million in Q2 2026, driven by reduced G&A spending.
• General and Administrative (G&A) expenses decreased 44% to $1.0 million due to lower professional fees and stock compensation.
• Research and Development (R&D) expenses increased to $1.8 million from $1.1 million, reflecting timing of clinical trial activities and translational analysis.
• The company met going concern requirements and intends to strengthen its balance sheet through partnerships, non-dilutive funding, and potential equity/debt financing.

Guidance and Future Outlook:

• U.S. activation for the Phase II ARDS trial is in final stages, with dosing expected to begin before year-end 2026.
• Comparative readout for the randomized ARDS study is projected for 2027, targeting an adaptive Phase 2B/3 seamless design.
• FDA meeting scheduled before year-end to discuss trial design, specifically regarding hierarchical endpoints and the potential for randomized Phase II data to contribute to a registration-enabling Phase 3.
• First patient dosing for the Phase I GVHD prevention study at University of Wisconsin is anticipated in H2 2026.
• Data readout for the Scripps Institute-sponsored MSS colorectal cancer study is expected in early 2027.
• Long-term goal involves expanding the Named Patient Program to additional international markets and advancing the ARPA-H BOSS program to enable room-temperature storage of cell therapies.

Business Segments and Product Lines:

• Agent 797 (INKT Cell Therapy): Active in the global Named Patient Program for paid, per-patient access outside the U.S.; currently enrolling in a randomized Phase II study for Acute Respiratory Distress Syndrome (ARDS) in Lviv, Ukraine, with U.S. sites activating soon.
• Colorectal Cancer Program: Investigational combination of Agent 797, botansilumab, and balacilumab for metastatic microsatellite-stable (MSS) colorectal cancer with liver metastases; currently enrolling at Scripps.
• Senolytic & Fibrosis Platform: Agent 797 and MINK215 (FAP-targeted IL-15 CAR-INKT) demonstrated ability to clear senescent cells in preclinical models, targeting interstitial lung disease and fibrosis.
• GVHD Prevention: Phase I investigator-sponsored study activating at University of Wisconsin, fully funded externally.
• ARPA-H BOSS Program: Selected as a therapy provider for a $87 million, four-year federal program aimed at stabilizing living medicines for room-temperature storage and deployment.

Market and Competitive Landscape:

• Target ARDS population estimated at ~93,000 U.S. patients annually; currently no approved drugs exist to reduce mortality in this unmet need space.
• Competitors include TLR4 agonists (e.g., ADESA-QR), but Agent 797 offers a multimodal approach combining anti-inflammatory, pathogen clearance, and tissue repair functions.
• Clinical differentiation relies on "off-the-shelf" allogeneic cells that require no apheresis, HLA matching, or lymphodepletion, allowing rapid administration within days of injury.
• Market trends highlight post-COVID persistence of hyper-inflammatory phenotypes and chronic pulmonary disability, driving demand for therapies that mitigate acute inflammation to prevent long-term fibrosis.

Risks and Challenges:

• Clinical trial execution risks include enrollment speeds and potential variability in standard of care across different geographies (e.g., Lviv vs. U.S.).
• Regulatory uncertainty regarding the acceptance of hierarchical endpoints (survival without ECMO) and the seamless transition from Phase 2 to Phase 3.
• Dependence on named patient programs for early revenue, which may be sporadic due to case-by-case regulatory authorizations.
• Technical challenge of maintaining allogeneic cell viability in cold chain logistics; success of ARPA-H BOSS program is critical for future scalability.

Management Commentary and Tone:

• Tone is confident and optimistic, emphasizing the transition from biological validation to randomized clinical evidence.
• CEO Dr. Buell highlighted that three strategic pillars (randomized trials, data accumulation, and physician demand) are now fully in motion.
• Management stressed the platform's versatility across critical illness, cancer, and fibrosis, viewing the underlying pathology as a shared loss of coordinated immune function.
• CFO Melissa Orlall noted a strategic shift to reduce non-essential spending while prioritizing funding for the pivotal ARDS readout.

Analyst Questions and Answers:

• Question on Treatment Effect & Landscape: Analyst asked for assumed treatment effect on mortality/ECMO usage and context regarding recent licensing deals.
  • Answer: Management confirmed 28-day mortality remains consistent with prior Phase 1/2 observations (~70-75% survival vs. ~40-50% with standard care). They emphasized rigorous center selection in Ukraine and upcoming U.S. sites to ensure U.S.-like standard of care (ventilator settings, proning, ECMO escalation).
• Question on FDA Alignment: Analyst inquired about biomarkers and FDA meeting topics (endpoints, patient counting).
  • Answer: Company is developing proprietary predictive biomarkers to identify responders and stratify patients; these will be discussed with the FDA. The proposed endpoint is a hierarchical "win ratio" focusing on survival without VV ECMO at day 14 and all-cause mortality at day 28. Management seeks alignment to allow Phase 2 patients to contribute to a seamless Phase 3 cohort.
• Question on Colorectal Data: Analyst asked for enrollment status and readout timeline.
  • Answer: The Scripps study is actively enrolling past safety cohorts with a meaningful patient count; readout expected in early 2027 with a presentation plan at a major GI conference.

Other Key Points:

• Agent 797 demonstrated the ability to clear multi-drug-resistant pathogens and resolve fever/oxygenation issues in early treated patients in conflict zones.
• The therapeutic approach targets the spectrum from acute inflammation to chronic fibrosis by clearing senescent cells and modulating immune responses.
• The ARPA-H BOSS selection validates the technology's potential to be "stockpiled" like conventional drugs, removing the single largest barrier to allogeneic cell therapy access.
• All externally funded studies (Colorectal, GVHD, ARPA-H) are non-dilutive, allowing the company to advance multiple programs without depleting cash reserves.